

1 **AMENDMENTS TO THE CLAIMS**

2

3 1. (Currently Amended). A therapeutic solution comprised of
4 filtered seawater ~~and firstly administered~~ in the form of an
5 aerosolized solution in the respiratory tract of mammals, said
6 therapeutic solution having a direct effect in respiratory tissues
7 and secretions as expectorant, mucolytic, decongestant and
8 virucidal, wherein said filtered seawater comprises
9 approximately from 277.00 to 555.00 millimoles per liter of
10 sodium, 417.00 to 894.00 millimoles per liter of chloride, 9.80 to
11 11.70 millimoles per liter of potassium, 20.90 to 26.13 millimoles
12 per liter of sulfate, 45.60 to 60.49 millimoles per liter of
13 magnesium, and 8.11 to 10.87 millimoles per liter of calcium,
14 wherein osmolality is from 920 to 1,130 mOsm/L/Kg and pH is
15 between 5.7 and 6.8.

16

17 2. (Canceled).

18

19 3. (Canceled).

20

21 4. (Original). The therapeutic solution set forth in claim 3, further
22 characterized in that said filtered seawater comprises trace
23 elements and a therapeutic solvent, said therapeutic solvent is
24 said seawater.

25

26 5. (Currently Amended). The therapeutic solution set forth in
27 claim 4, further characterized in that said therapeutic solution is
28 ~~said firstly administered by aerosol to said respiratory tract of~~

1 said mammals such that said therapeutic solution contacts
2 areas where said mucosa secretions accumulate including nose,
3 pharynx, larynx, trachea, bronchi, bronchioles and alveoli.
4

5 6. (Currently Amended). The therapeutic solution set forth in
6 claim 5, further characterized in that said therapeutic solution is
7 secondly—administered by nebulization with a dose of
8 approximately between one to ten ml via nasal or oral cavity to
9 reach intratracheobronchial tissues and secretions with a
10 varying frequency of administration according said mammals
11 age group and clinical diagnosis, said nebulization every two to
12 twelve hours and extending three to fifteen minutes, said
13 therapeutic solution may be thirdly administered in a dry form
14 through inhalations of one to three per time.

15
16 7. (Currently Amended). The therapeutic solution set forth in
17 claim 5, further characterized in that said therapeutic solution is
18 fourthly—administered with tents and/or or a vaporization
19 system in a continuous form for up to twenty-four hours or
20 more.

21
22 8. (Currently Amended). A method of affecting for treating
23 respiratory tissues and secretions as expectorant, mucolytic,
24 decongestant and virucidal in a mammal in need thereof,
25 comprising administering to said mammal an effective amount
26 of a therapeutic solution, said therapeutic solution comprised of
27 filtered seawater and firstly administered in the form of an
28 aerosolized solution via nasal or cavity by nebulization with a

1 dose of approximately between one to ten ml. with varying
2 frequency of administration according to said mammal's age
3 group and clinical diagnosis. said nebulization administered
4 every two to twelve hours, extending three to fifteen minutes to
5 reach intratracheobronchial tissues and secretions and said
6 solution increases the solubility and volume of the phlegm in a
7 respiratory tract reducing the adhesiveness and making them
8 easier to expel by means of coughing or suctioning, providing a
9 symptomatic relief of cough and congestion associated with
10 bronchial asthma, acute and chronic bronchitis and common
11 colds, and wherein said solution increases output of said
12 secretions from said respiratory tract by stimulating ciliary
13 movement which facilitates the removal of mucus and said
14 solution stimulates water transport into an airway lumen to
15 decrease the inflammatory changes in a respiratory tree
16 associated with bronchial asthma, chronic bronchitis and
17 common colds.

18
19 9. (Canceled).

20
21 10. (Canceled).

22
23 11. (Canceled).

24
25 12. (Canceled).

26
27 13. (Canceled).

1 14. (Original). A method of preparing a therapeutic solution,
2 comprising:

3

4 A) extracting seawater from a depth beyond where microscopic
5 organism known as plankton lives, in an ocean;

6

7 B) filtering said seawater to obtain desired concentration of
8 elements, said elements primarily comprising sodium, magnesium,
9 calcium, potassium, chloride, and sulfate;

10

11 C) testing said seawater for microbiological and chemical analysis;
12 and

13

14 D) preparing a solution for packaging, having a predetermined
15 approximated seawater element content as expectorant, mucolytic,
16 decongestant, and virucidal.

17

18 15. (New). The solution set forth in claim 12 wherein said solution
19 is used as a vehicle for delivering drugs into the respiratory tract of a
20 mammal.

21

22